{"query":"Beta Bionics Sean Saint iLet bionic pancreas news","follow_up_questions":null,"answer":null,"images":[],"results":[{"url":"https://investors.betabionics.com/news-releases/news-release-details/beta-bionics-announces-launch-ilet-bionic-pancreas-abbotts","title":"Beta Bionics Announces Launch of the iLet Bionic Pancreas with ...","content":"The iLet is the first insulin delivery system in the United States to connect to Abbott's FreeStyle Libre 3 Plus sensor, whose readings every minute will help","score":0.99991965,"raw_content":null},{"url":"https://investors.betabionics.com/news-releases/news-release-details/beta-bionics-announces-agreement-abbott-integrate-ilet-bionic","title":"Beta Bionics Announces Agreement with Abbott to Integrate the iLet ...","content":"## Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott’s Future Dual Glucose-Ketone Sensor. IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S. The iLet represents a significant advancement in diabetes care as the first and only AID system that makes 100% of insulin dosing decisions automatically. The system currently supports Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring sensor, and this future design further extends the collaboration between Beta Bionics and Abbott, reinforcing their shared commitment to bringing cutting-edge diabetes solutions to the market. “As the benchmark in automated insulin delivery systems, the iLet will naturally integrate with Abbott's future dual glucose-ketone sensor as soon as it becomes commercially available.”.","score":0.99991584,"raw_content":null},{"url":"https://www.betabionics.com/about-us/our-team/sean-saint/","title":"Sean Saint | CEO & Board Member - Beta Bionics","content":"DO NOT start to use the iLet Bionic Pancreas System without adequate training. Incorrect use may result in over-delivery or under-delivery of insulin, which","score":0.9999008,"raw_content":null},{"url":"https://www.facebook.com/schwabnetwork/videos/sean-saint-beta-bionics-bbnx-ceo-on-todays-ipo/528137660388649/","title":"Sean Saint: Beta Bionics (BBNX) CEO On Today's IPO - Facebook","content":"Beta Bionics ($BBNX) makes its IPO today, and CEO Sean Saint joined Oliver Renick to give an overview of the company. \"The iLet Bionic Pancreas:","score":0.99983263,"raw_content":null},{"url":"https://www.nasdaq.com/articles/beta-bionics-inc-announces-integration-ilet-bionic-pancreas-abbotts-future-dual-glucose","title":"Beta Bionics, Inc. Announces Integration of iLet Bionic Pancreas ...","content":"Beta Bionics plans to integrate its iLet Bionic Pancreas with Abbott's upcoming dual glucose-ketone sensor for enhanced diabetes management. Beta Bionics, Inc. has announced plans to integrate its iLet Bionic Pancreas automated insulin delivery system with Abbott’s upcoming dual glucose-ketone sensor in the United States. * Beta Bionics is expanding its innovative diabetes management solutions by integrating its iLet Bionic Pancreas with Abbott's future dual glucose-ketone sensor, enhancing its product offering. Beta Bionics is integrating its iLet system with Abbott's upcoming dual glucose-ketone sensor to enhance diabetes care solutions. IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S. The iLet represents a significant advancement in diabetes care as the first and only AID system that makes 100% of insulin dosing decisions automatically.","score":0.99982053,"raw_content":null}],"response_time":1.57,"request_id":"8363afb9-d274-46b2-acc4-ece0060723b7"}